MK-677 (ibutamoren) has no approved label, so every dose figure here traces back to its published human trials rather than a prescribing guideline. Across studies in healthy older adults, hip-fracture recovery, and Alzheimer's disease, the dose tested was an oral 25 mg once daily.[1][2][3]
Reviewed for accuracy · Last reviewed July 8, 2026Across the published human trials, the dose studied was a single oral 25 mg once daily. This describes what was tested, not a recommendation:
Because MK-677 is a non-peptide small molecule taken by mouth, there is no injection or reconstitution step. Treat the 25 mg once-daily figure as a description of what was studied, not a recommendation, and note that the trials measured biomarker and body-composition changes rather than validating a dose for everyday use.
This page is an independent educational reference and is not medical advice, and does not indicate any approval status for any use. MK-677 is a non-peptide research compound and is not FDA-approved. Talk to a doctor before starting any compound.